Evidence map›Paper›PMID 24696476›Full record

ArticleJournal of virology2014

HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.

Rémi Planès, Lbachir BenMohamed, Kaoutar Leghmari, Pierre Delobel, Jacques Izopet, Elmostafa Bahraoui

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Programmed death-ligand 1 on ex vivo-expanded toll-like-receptor-Bregs prevents allograft rejection by Breg viability promotion, CD4American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  5. Article
  6. Article
  7. The PD-1/PD-L1 pathway and Epstein-Barr virus.European journal of medical research · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Rémi PlanèsINSERM, U1043, Toulouse, France CNRS, U5282, Toulouse, France Université Paul Sabatier Toulouse, Toulouse, France.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Kaoutar LeghmariINSERM, U1043, Toulouse, France CNRS, U5282, Toulouse, France Université Paul Sabatier Toulouse, Toulouse, France.
Pierre DelobelINSERM, U1043, Toulouse, France CNRS, U5282, Toulouse, France Université Paul Sabatier Toulouse, Toulouse, France Department of Infectious Diseases, Toulouse University Hospital, Toulouse, France.
Jacques IzopetINSERM, U1043, Toulouse, France CNRS, U5282, Toulouse, France Université Paul Sabatier Toulouse, Toulouse, France Department of Virology, CHU Purpan, Toulouse, France.
Elmostafa BahraouiINSERM, U1043, Toulouse, France CNRS, U5282, Toulouse, France Université Paul Sabatier Toulouse, Toulouse, France bahraoui@cict.fr.
Centre National de la Recherche Scientifique · FRUniversité Toulouse III - Paul Sabatier · FRUniversity of California, Irvine · US

Funding

Therapeutic Ocular HSV Vaccine in HLA Transgenic RabbitsR01EY019896 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2010 to 2025
$5.1M
Ocular Mucsoal Immunity Induced by HSV-1 LipopeptidesR01EY014900 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2003 to 2014
$3.1M
NEI NIH HHS EY019896NEI NIH HHS EY14900NEI NIH HHS R01 EY014900NEI NIH HHS R01 EY019896
6 · The paper itself

Abstract

unlabelledChronic human immunodeficiency virus type 1 (HIV-1) infection is associated with induction of T-cell coinhibitory pathways. However, the mechanisms by which HIV-1 induces upregulation of coinhibitory molecules remain to be fully elucidated. The aim of the present study was to determine whether and how HIV-1 Tat protein, an immunosuppressive viral factor, induces the PD-1/PD-L1 coinhibitory pathway on human dendritic cells (DCs). We found that treatment of DCs with whole HIV-1 Tat protein significantly upregulated the level of expression of PD-L1. This PD-L1 upregulation was observed in monocyte-derived dendritic cells (MoDCs) obtained from either uninfected or HIV-1-infected patients as well as in primary myeloid DCs from HIV-negative donors. In contrast, no effect on the expression of PD-L2 or PD-1 molecules was detected. The induction of PD-L1 on MoDCs by HIV-1 Tat (i) occurred in dose- and time-dependent manners, (ii) was mediated by the N-terminal 1-45 fragment of Tat, (iii) did not require direct cell-cell contact but appeared rather to be mediated by soluble factor(s), (iv) was abrogated following neutralization of tumor necrosis factor alpha (TNF-α) or blocking of Toll-like receptor 4 (TLR4), (v) was absent in TLR4-knockoout (KO) mice but could be restored following incubation with Tat-conditioned medium from wild-type DCs, (vi) impaired the capacity of MoDCs to functionally stimulate T cells, and (vii) was not reversed functionally following PD-1/PD-L1 pathway blockade, suggesting the implication of other Tat-mediated coinhibitory pathways. Our results demonstrate that HIV-1 Tat protein upregulates PD-L1 expression on MoDCs through TNF-α- and TLR4-mediated mechanisms, functionally compromising the ability of DCs to stimulate T cells. The findings offer a novel potential molecular target for the development of an anti-HIV-1 treatment. IMPORTANCE: The objective of this study was to investigate the effect of human immunodeficiency virus type 1 (HIV-1) Tat on the PD-1/PD-L1 coinhibitory pathway on human monocyte-derived dendritic cells (MoDCs). We found that treatment of MoDCs from either healthy or HIV-1-infected patients with HIV-1 Tat protein stimulated the expression of PD-L1. We demonstrate that this stimulation was mediated through an indirect mechanism, involving tumor necrosis factor alpha (TNF-α) and Toll-like receptor 4 (TLR4) pathways, and resulted in compromised ability of Tat-treated MoDCs to functionally stimulate T-cell proliferation.

Indexed as

Amino Acid MotifsAnimalsB7-H1 AntigenCell ProliferationCells, CulturedDendritic CellsHIV-1HIV InfectionsHumansMiceMice, Inbred C57BLMice, KnockoutMonocytestat Gene Products, Human Immunodeficiency VirusT-LymphocytesToll-Like Receptor 4B7-H1 Antigentat Gene Products, Human Immunodeficiency VirusToll-Like Receptor 4Tumor Necrosis Factor-alpha

Identifiers

PMID24696476
PMCPMC4054384
OpenAlexW2141884204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.